Alberta reaches deal to donate imported children's pain medication to Ukraine
Montreal-based Health Partners International of Canada (HPIC) told Postmedia on Tuesday that it had struck an agreement with Alberta Health Services (AHS) to accept as many as 1.4 million bottles of acetaminophen and ibuprofen to donate to the war-torn European country.
The organization says once the donation is received, it will work with partner organizations and local government to identify where the supply is most needed.
'In essence we match what is needed to what we have available,' HIPC president Lois Brown stated in an email.
'Agreements with recipient partners include guarantees that all donated medicines will be used in accordance with applicable standard treatment guidelines.'
HIPC partner organizations typically cover the costs of transportation for donated supplies.
In April, Health Canada told Postmedia it had issued a 'no objection' letter in March to Alberta's request to donate the medication to Ukraine.
The letter requires Alberta to ensure the drugs are only sold or donated abroad for humanitarian purposes, don't violate Ukrainian laws including import approvals, and that logistics and quality oversight are overseen by a compliant drug establishment licence holder.
Turkish-base drug manufacturer Atabay had been seeking that licence though its status remains unclear.
Postmedia's queries regarding the licence as well as details on quantity, timing, and cost were directed to the office of Hospital and Surgical Health Services Minister Matt Jones.
AHS has previously said it was not part of the process of finalizing a donation agreement.
The medication was imported in 2023 under exceptional circumstances amid a Canada-wide shortage, and is set to expire between January and March of next year, according to internal documents previously obtained by Postmedia.
Less than a third of the planned shipment arrived, and much of the medication that did make it to Alberta went unused after the shortage ended.
The imported acetaminophen proved unpopular due to its weaker dosage, and AHS told hospital staff to stop using the it six months after it arrived, in part because its thicker consistency posed a risk of clogging feeding tubes.
The province's plan to recoup some costs by selling some of its supply to other provinces was abandoned amid unanimous lack of interest, and concern over its dosage, which is more common in Europe.
Primary and Preventative Health Services Adriana LaGrange served as the health minister until mid-May when the province split the health portfolio into four new roles.
In March, LaGrange described the medication as 'good quality drugs.'
'If we can't use them in Alberta, then we should be sending them to other countries,' she said.
The $70-million deal in 2022 to bring in what was to be five million bottles of acetaminophen and ibuprofen has come under scrutiny following allegations of corruption by the former head of AHS regarding the procurement and contracting process.
Those allegations have not been tested in court, and the government denies wrongdoing, but several inquiries into the deal are underway including the government's own investigation as well as others by the RCMP and Alberta's auditor general.
As of last December, $49 million of the government's contract with Atabay remains unfulfilled, with the province seeking fulfill the balance by importing an intravenous adult pain medication.
HIPC says it is the only Canadian charity licensed by Health Canada to handle donated medicines and has delivered more than $735 million in donated medicines and related supplies together with its partner organizations to over 130 countries since 1990.
mblack@postmedia.com
Bookmark our website and support our journalism: Don't miss the news you need to know — add EdmontonJournal.com and EdmontonSun.com to your bookmarks and sign up for our newsletters here.
You can also support our journalism by becoming a digital subscriber. Subscribers gain unlimited access to The Edmonton Journal, Edmonton Sun, National Post and 13 other Canadian news sites. Support us by subscribing today: The Edmonton Journal | The Edmonton Sun.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Do Wall Street Analysts Like Solventum Stock?
With a market cap of $12.4 billion, Solventum Corporation (SOLV) is an independent healthcare company that develops, manufactures, and markets innovative solutions to meet critical patient and customer needs worldwide. Its business spans four segments: Medsurg; Dental Solutions; Health Information Systems; and Purification and Filtration, serving healthcare providers through direct sales, distribution, and digital platforms. Shares of the Maplewood, Minnesota-based company have outperformed the broader market over the past 52 weeks. SOLV stock has increased 21.4% over this time frame, while the broader S&P 500 Index ($SPX) has gained 16.4%. However, shares of the company have risen 8.1% on a YTD basis, lagging behind SPX's 9.7% return. More News from Barchart Lyft Generates Huge FCF Margins - LYFT Stock Is Too Cheap Trade the Warren Buffett Rally in UnitedHealth Stock With This High-Reward, Low-Risk Options Strategy Powell, Trump Talks and Other Can't Miss Items this Week Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Looking closer, Solventum stock has also outpaced the Health Care Select Sector SPDR Fund's (XLV) 10.8% decrease over the past 52 weeks. Shares of Solventum rose 2% on Aug. 7 after the company reported Q2 2025 adjusted EPS of $1.69 and revenue of $2.2 billion, above Wall Street forecasts. Growth was driven largely by its MedSurg segment, where sales rose 4.8% to $1.2 billion, reflecting robust demand for wound care and surgical sterilization products, alongside lower expenses. Additionally, management raised its full-year adjusted EPS guidance to $5.80 - $5.95, as easing U.S.-China tariff risks reduced expected headwinds. For the fiscal year ending in December 2025, analysts expect SOLV's adjusted EPS to decline 11.9% year-over-year to $5.90. The company's earnings surprise history is mixed. It topped the consensus estimates in three of the last four quarters while missing on another occasion. Among the 13 analysts covering the stock, the consensus rating is a 'Moderate Buy.' That's based on four 'Strong Buy' ratings, eight 'Holds,' and one 'Strong Sell.' This configuration is more bullish than three months ago, with one 'Strong Buy' rating on the stock. On Aug. 8, Piper Sandler increased its price target on Solventum to $94 while maintaining an 'Overweight' rating. As of writing, the stock is trading below the mean price target of $87.12. The Street-high price target of $103 implies a modest potential upside of 44.2% from the current price levels. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Los Angeles Times
an hour ago
- Los Angeles Times
U.S. pediatricians' new COVID-19 vaccine recommendations differ from CDC advice
NEW YORK — For the first time in 30 years, the American Academy of Pediatrics is substantially diverging from U.S. government vaccine recommendations. The group's new COVID-19 recommendations — released Tuesday — come amid a tumultuous year for public health, as vaccine skeptics have come into power in the new Trump administration and government guidance has become increasingly confusing. This isn't going to help, acknowledged Dr. James Campbell, vice chair of the AAP infectious diseases committee. 'It is going to be somewhat confusing. But our opinion is we need to make the right choices for children to protect them,' he added. The AAP is strongly recommending COVID-19 shots for children ages 6 months to 2 years. Shots also are advised for older children if parents want their kids vaccinated, the AAP said. That differs from guidance established under U.S. Health Secretary Robert F. Kennedy Jr., which doesn't recommend the shots for healthy children of any age but says kids may get the shots in consultation with physicians. Children ages 6 months to 2 years are at high risk for severe illness from COVID-19, and it was important that recommendations continue to emphasize the need for them to get vaccinated, said Campbell, a University of Maryland infectious diseases expert. Vaccinations also are recommended for older children who have chronic lung diseases or other conditions that put them at higher risk for severe disease, the AAP said. In a statement, Department of Health and Human Services spokesperson Andrew Nixon said 'the AAP is undermining national immunization policymaking with baseless political attacks.' He accused the group of putting commercial interests ahead of public health, noting that vaccine manufacturers have been donors to the AAP's Friends of Children Fund. The fund is currently paying for projects on a range of topics, including health equity and prevention of injuries and deaths from firearms. The 95-year-old Itasca, Illinois-based organization has issued vaccination recommendations for children since the 1930s. In 1995, it synced its advice with recommendations made by the federal government's Centers for Disease Control and Prevention. There have been a few small differences between AAP and CDC recommendations since then. For example, the AAP has advised that children get HPV vaccinations starting at age 9; the CDC says that's OK but has emphasized vaccinations at ages 11 and 12. But in 30 years, this is the first time the recommendations have differed 'in a significant or substantial way,' Campbell said. Until recently, the CDC — following recommendations by infectious disease experts — has been urging annual COVID-19 boosters for all Americans ages 6 months and older. But in May, U.S. Health Secretary Robert F. Kennedy Jr. announced that COVID-19 vaccines are no longer recommended for healthy children and pregnant women. A few days later, the CDC issued language that healthy children may get the shots, but that there was no longer a 'should' recommendation. The idea that healthy older kids may be able to skip COVID-19 boosters has been brewing for some time among public health experts. As the COVID-19 pandemic has waned, experts have increasingly discussed the possibility of focusing vaccination efforts on people 65 and older — who are among those most as risk for death and hospitalization. A CDC expert panel in June was set to make recommendations about the fall shots. Among the options the panel was considering was whether suggest shots for high-risk groups but still giving lower-risk people the choice to get vaccinated. But Kennedy bypassed the group, and also decided to dismiss the 17-member panel and appoint his own, smaller panel, that included vaccine skeptics. Kennedy also later excluded the AAP, the American Medical Association and other top medical organizations from working with the advisers to establish vaccination recommendations. Kennedy's new vaccine panel has yet to vote on COVID-19 shot recommendations. The panel did endorse continuing to recommend fall flu vaccinations, but also made a decision that led to another notable difference with the AAP. The new advisory panel voted that people should only get flu vaccines that are packaged as single doses and do not contain the preservative thimerosal. The AAP said there is no evidence of harm from the preservative, and recommended doctors use any licensed flu vaccine product that's appropriate for the patient. Stobbe writes for the Associated Press. The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
UPI
an hour ago
- UPI
FDA warns against eating possible radioactive shrimp sold at Walmart
Aug. 19 (UPI) -- The U.S. Food and Drug Administration issued a public warning to not eat certain Great Value shrimp sold at Walmart because of it being possibly linked to contamination with the radioactive isotope Cesium-137. U.S. Customs and Border Protection detected possible Cesium-137, or Cs-137, in U.S.-bound shipments at four American ports of entry, the FDA said Tuesday in a release. However, U.S. heath officials added "at this time" no store product in U.S. markets has tested positive for Cesium-137 contamination. The health agency specifically alerted consumers about three Great Value brand frozen raw shrimps with a lot code: 8005540-1, and a best-by dates of March 15, 2027. In addition, there are other lot codes involved: 8005538-1 and 8005539-1. FDA officials said testing at the company distributor in Indonesia also tested positive. The FDA is working with distributors and retailers that may have received the tainted product from Indonesia-based PT. Bahari Makmur Sejati, which is doing business as BMS Foods. FDA officials said all products from the company are banned from U.S. entry "until the firm has resolved the conditions that gave rise to the appearance of the violation." "If you have recently purchased raw frozen shrimp from Walmart that matches this description, throw it away," the FDA advised in its release. The FDA's investigation is ongoing.
